HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

AMG-714

an anti-IL-15 monoclonal antibody

Also Known As:

AMG 714; ordesekimab

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Leon, Francisco: 2 articles (12/2019 - 12/2019)
2.	Parnes, Jane R: 2 articles (12/2019 - 12/2019)
3.	Bouma, Gerd: 1 article (12/2019)
4.	Butz, Eric: 1 article (12/2019)
5.	Cellier, Christophe: 1 article (12/2019)
6.	Cerf-Bensussan, Nadine: 1 article (12/2019)
7.	Collin, Pekka: 1 article (12/2019)
8.	Crespo, Laura: 1 article (12/2019)
9.	Crowe, Sheila E: 1 article (12/2019)
10.	Green, Peter H R: 1 article (12/2019)

Related Diseases

1.	Nasopharyngitis 12/01/2019 - "The most common adverse event in the AMG 714 group was nasopharyngitis (eight [42%] patients vs one [11%] in the placebo group). "
2.	Inflammation (Inflammations) 12/01/2022 - "Taken together, these data demonstrate that ADCC is not a potential liability for ordesekimab and does not contribute to the reduction of IL-15-mediated inflammation, the intended pharmacological effect."
3.	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 12/01/2019 - "The most common treatment-emergent adverse events were gastrointestinal disorders (17 [77%] participants in the 150 mg AMG 714 group, 16 [76%] in the 300 mg AMG 714 group, and 13 [68%] in the placebo group). "
4.	Celiac Disease (Celiac Sprue) 12/01/2022 - "Ordesekimab (AMG 714 or PRV-015), a fully human immunoglobulin G1-kappa anti-interleukin (IL)-15 monoclonal antibody, is in clinical development for celiac disease. "
5.	Injection Site Reaction 12/01/2019 - "Injection site reactions were the most common individual adverse event, reported in eight (36%) patients in the 150 mg AMG 714 group, 11 (52%) in the 300 mg group, and five (26%) in the placebo group. "

Related Drugs and Biologics

1.	AMG-714
2.	Interleukins
3.	Immunoglobulins (Immunoglobulin)
4.	Monoclonal Antibodies